In September, Cure Alzheimer’s Fund representatives were invited by the White House to be panelists at a briefing on Alzheimer’s disease. At the White House Briefing on the Challenge of Alzheimer’s Disease in the United States, Tim Armour and Rudy Tanzi made presentations regarding the current state of Alzheimer’s research to senior members of the White House, Department of Health and Human Services, National Institutes of Health and representatives of many Alzheimer’s advocacy groups.
Fresh off of summiting Aconcagua, the highest peak in South America, Alan Arnette is at it again. This spring, he will attempt to summit Everest—the highest peak on Earth at 29,035 feet. Everest is the third mountain in his 7 Summits Climb for Alzheimer’s: Memories are Everything campaign—his yearlong mission to scale the highest peak on each of the seven continents to raise money for the fight against Alzheimer’s.
A meeting of the minds
One of the most important, outstanding genetic questions about Alzheimer’s disease is the relationship between the APOE genotype and the risk associated with the disease. To better understand this topic and speed progress, Cure Alzheimer’s Fund (CAF) sponsored a meeting in February 2010 to explore this issue. The body of biological knowledge regarding how and why APOE likely is linked with AD was discussed in detail by members of the CAF Research Consortium and Cheryl Wellington, Ph.D., University of British Columbia; Michael Brown, M.D., University of Texas; Karl Weisgraber, Ph.D., Gladstone Institute; Alan Tall, Ph.D., Columbia University; and Joachim Herz, M.D., University of Texas, whose record of research includes valuable insights into this relationship. The meeting led to some important, newly funded research, including a project by David Holtzman, M.D., in his lab at Washington University in St. Louis.
© 2005-2017 Cure Alzheimer's Fund. All rights reserved.